Inhibitors of protein prenylation 1999
- 1 September 1999
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 9 (9) , 1263-1280
Abstract
Interest in farnesyltransferase inhibitors (FTIs) as a potential cancer therapy continues, judging from the approximately eighty patent applications published in the fourteen month period from January 1998. This review summarises progress in the field since the previous update [1] and includes a description of the first clinical trials in man. Also discussed are current biological experiments designed to further understand the preclinical antiproliferative effects of FTIs. Recent structural studies of farnesyltransferase (FTase) are summarised. Novel FTIs appearing in the scientific and patent literature in the past year are reviewed, along with new data published on key compounds, such as those undergoing clinical evaluation.Keywords
This publication has 39 references indexed in Scilit:
- Prenyltransferase Inhibitors Induce Apoptosis in Proliferating Thyroid Cells through a p53-Independent, CrmA-Sensitive, and Caspase-3-Like Protease- Dependent Mechanism1Endocrinology, 1999
- Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cellsProceedings of the National Academy of Sciences, 1998
- Crystal Structure of Farnesyl Protein Transferase Complexed with a CaaX Peptide and Farnesyl Diphosphate AnalogueBiochemistry, 1998
- H-Ras Peptide and Protein Substrates Bind Protein Farnesyltransferase as an Ionized ThiolateBiochemistry, 1998
- Cocrystal Structure of Protein Farnesyltransferase Complexed with a Farnesyl Diphosphate Substrate,Biochemistry, 1998
- Protein Farnesyltransferase: Structure and Implications for Substrate BindingBiochemistry, 1998
- Inhibitors of protein farnesylation 1998Expert Opinion on Therapeutic Patents, 1998
- Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenograftsOncogene, 1998
- Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilonesProceedings of the National Academy of Sciences, 1998
- A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and ApoptosisMolecular and Cellular Biology, 1998